• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PRF Technologies Ltd.

    3/3/26 4:15:07 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    6-K 1 zk2634487.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 6-K
     
    Report of Foreign Private Issuer
     
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934
     
    For the month of March 2026
     
    Commission File Number: 001-39481
     
    PRF Technologies Ltd.
    (Translation of registrant’s name into English)
     
    65 Yigal Alon St., Tel Aviv 6744316
    Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒             Form 40-F ☐

    This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-282264, 333-254982, 333-276485, 333-277594, 333-283655 and 333-286941), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.



    On February 25, 2026, the Board of Directors (the “Board”) of PRF Technologies Ltd. (the “Company”) appointed Mr. Efi Cohen-Arazi as interim Chief Executive Officer (“CEO”) of the Company, effective immediately, replacing Mr. Ehud Geller, who concurrently ceased serving as interim CEO. Mr. Geller will continue to serve as Executive Chairman of the Board. In connection with this appointment, Mr. Cohen-Arazi resigned, effective immediately, from the Audit Committee and Compensation Committee, but will continue to serve as a member of the Board. The Board appointed Mr. Asaf Shavit, effective immediately, to fill the resulting vacancies on both committees. Additionally, the Board appointed Mr. Eyal Broder, who has been serving as interim Chief Financial Officer (“CFO”) of the Company since October 2024, as CFO on a permanent basis.

    Except for the change in position, Mr. Broder’s compensation and the terms and conditions of his existing employment agreement remain unchanged. The Company expects to enter into an employment agreement with Mr. Cohen-Arazi in connection with his appointment as the interim CEO.

    The Board has determined that Mr. Shavit is independent under the applicable rules of the SEC and The Nasdaq Stock Market.

    The resignations of Mr. Cohen-Arazi and Mr. Geller from the Audit and Compensation Committees of the Board and as the interim CEO, respectively, were not the result of any disagreement with the Company, the Board or the Company’s management on any matter relating to the Company’s operations, policies, practices or otherwise.

    Background of New Interim CEO, CFO and Member of the Audit and Compensation Committees

    Mr. Efi Cohen-Arazi has served as a director of the company since 2020. Mr. Arazi was the Co-Founder & CEO of Rainbow Medical, Israel’s leading medical device innovation house since 2008. From 2004 to 2006 Mr. Cohen Arazi served as the CEO and Co-Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen Arazi served as a board director for numerous biotech/medtech companies since 2005. Mr. Cohen-Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at Merck-Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen-Arazi graduated summa cum laude with a M.Sc. degree from the Hebrew University of Jerusalem, Israel.

    Mr. Eyal Broder has served as the Company’s Interim CFO since October 2024, and as the Company’s Finance Director since February 2023. Previously, Mr. Broder served as CFO at several industry-leading companies, including Inomize, Tradenet Group, Elbit Imaging India and Director of Finance at Koor Industries Ltd. Mr. Broder holds a BA in Accounting and Economics and an MBA in Business Management, both from Tel Aviv University.

    Mr. Asaf Shavit has served as a director of the Company since September 2025. Mr. Shavit has more than 35 years of experience providing audit, tax and financial advisory services to public and private companies, including public corporations and subsidiaries of foreign entities. His areas of expertise include audits of financial statements, budget planning and control, taxation, mergers and acquisitions, corporate liquidations, valuations, and complex cross-border and capital markets transactions. He currently serves as Managing Partner at Moalem-Shavit & Co., Certified Public Accountants, since 1995, where he leads a team of more than 14 professionals. Mr. Shavit holds a B.A. in Accounting, Economics and Business Management and an M.B.A. in Business Management with a concentration in Finance and Banking. He is also a Certified Public Accountant.


     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    Date: March 3, 2026
    PRF TECHNOLOGIES LTD.
     
     
     
    By:
    /s/ Ehud Geller
     
     
    Ehud Geller
    Executive Chairman of the Board
     

     
    Get the next $PRFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy

    TEL AVIV, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group (Electricite' De France, France's Electric Company, one of the largest international energy companies), a global leader in renewable energy, relating to an operational, utility-scale solar power plant in Israel. This engagement represents the next phase of Deep Solar's previously announced strategy and a new commercial revenue opportunity—an important milestone following the recent launch of Smart TDD. Pursuant to the agre

    2/18/26 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

    TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (NASDAQ:PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy. Under the agreement, DeepSolar will provide continuous analytics and performance monitoring designed to enhance operational visibility, support proactive asset management, and enable data-driven decision-making throughout the proje

    2/11/26 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

    Patent filing follows acceptance into the NVIDIA Connect Program  Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for utility-scale solar assets TEL AVIV, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that it has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling designed to significantly improve the accuracy of solar energy production forecasts in competitive electric utility markets. The patent follows acceptance into the prestigious NVIDIA Connect Program and

    1/20/26 9:05:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    3/3/26 4:15:07 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/18/26 9:38:03 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/11/26 8:54:35 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care